BRCA1 and cancer: When both BRCA1 and BRCA2 alleles are present, they show a selective toxicity to PARPi compared with when one wild-type allele is present.14,16 The discovery of this vulnerability led to significant efforts to develop PARPi to treat cancer patients with mutations in genes involved in the DSB repair pathway.